Having a "highly compliant" MSO model is expensive

Having a "highly compliant" MSO model is expensive to set up as it is costly to do the legal work. Generex has a lot of irons in the fire and only so much money as far as we know. Each state has to be looked at individually. The new MSO model might require the investors(medical professionals) to wait a long time(many months-years) to see a return that may be less(maybe a lot less) than the previous MSO model's they were invested. Of course, being more compliant will result in lower, yet safer ROI. Safer is great but you may get less traction in signing up investors, at least at first. You may not know, I participated in an investment call as I was(still am, once we get upcoming plans SUCCESSFULLY executed, unfortunately the recent retirement of shares was not successful IMO) interested in investing. The presentation was solid but I want to know we have up listed, completed the spin out and see revenue in the annual/quarterly reports. Until then we are just another OTC company full of hopes and dreams.

Why haven't we had reports of more states having been opened up?

That is why I am resetting my MSO timeframe for 18 months(Joe's Jan timeframe for a billion$) but starting the calendar on Nov 1, 2019 and lowering my expectation to $500M. I hope Generex gets to Joe's original estimate though!